Bayer's Challenge in 2014? For Xofigo to Win Share From Johnson & Johnson's Zytiga
The market for prostate cancer treatment is $12 billion and growing, but it's getting crowded. That makes this year important as Bayer's Xofigo faces off against Johnson's Zytiga and Medivation's Xtandit.
Dendreon Surges While Staples Gets Clipped
A yearlong exercise intent on proving that value and contrarian investing can be incredibly successful.
Will the Shorts Keep Hating Dendreon Corporation in 2014?
Dendreon was a favorite of short-sellers in 2013. Could 2014 be the year Dendreon gets some market love?
Dendreon Corporation (DNDN): New Analyst Report from Zacks Equity Research - Zacks Equity Research R
Dendreon Corporation (DNDN): New Analyst Report from Zacks Equity Research - Zacks Equity Research Report